Substance / Medication

Fondaparinux sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Fondaparinux sodium combined with conventional therapy improves subchorionic hematoma with protein S deficiency.
Tan Yan, Yan Zhenjiao, Chen Minhong et al. · Technol Health Care · 2025
PMID: 39240599RCT
Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China.
Li Yi-Yi, Zhong Xin-Jing, Luo Jun-Ting et al. · J Cardiovasc Pharmacol · 2024
PMID: 39240728RCT
Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery.
Sasaki Satoshi, Miyakoshi Naohisa, Matsuura Hiroshi et al. · J Orthop Sci · 2009
PMID: 19802659RCT
Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection.
Li Baiqiang, Wang Kang, Zhao Xin et al. · Chin J Traumatol · 2015
PMID: 26643240Observational
Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.
Klaeffling C, Piechottka G, Daemgen-von Brevern G et al. · Ther Drug Monit · 2006
PMID: 16778722Observational
Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Bjorvatn Afsane, Kristiansen Frode · Am J Cardiovasc Drugs · 2005
PMID: 15725043Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fondaparinux sodium (substance)
SNOMED CT
385517000
UMLS CUI
C1099664

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Fondaparinux sodium — Conditions, Biomarkers & Specialists | Healos | Healos